AstraZeneca's board has formally rejected Pfizer's "final" sweetened and enlarged £55-per-share bid tabled over the weekend, arguing that it still undervalues the UK pharma company's prospects.
阿斯利康(AstraZeneca)董事會已正式拒絕輝瑞(Pfizer)上周末提出的690億英鎊的收購價,表示這仍然低估了這家英國藥企的前景。此報價較此前已有提高,并附加了優惠條件。
您已閱讀11%(283字),剩余89%(2347字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。